VERTEX PHARMACEUTICALS INC / MA

VRTX Healthcare & Pharma 1/10 Low Risk
1/10

VERTEX PHARMACEUTICALS INC / MA did not report standard long-term debt figures in its most recent 10-K. Interest coverage stands at 52.9x. Overall, VRTX carries low refinancing risk (score 1/10).

Maturity Schedule

Year 1 $0 Year 2 $0 Year 3 $0 Year 4 $0 Year 5 $0 Beyond 5 $0
Period Amount Due % of Total
Year 1 (0-12 months) N/A N/A
Year 2 (12-24 months) N/A N/A
Year 3 (24-36 months) N/A N/A
Year 4 (36-48 months) N/A N/A
Year 5 (48-60 months) N/A N/A
Beyond 5 Years N/A N/A
Total Scheduled Maturities N/A 100.0%

Key Metrics

Total Long-Term Debt
N/A
Near-Term (12mo)
N/A
Interest Coverage
52.9x
Debt/Equity
N/A
Cash Coverage
N/A
Operating Income
$3.8B

Score Components

Component Value Weight
Near-Term Maturity Concentration N/A 30%
Interest Coverage Ratio 52.88x 25%
Debt-to-Equity Ratio N/A 25%
Cash Coverage of Near-Term Debt N/A 20%

Related Companies

JOHNSON & JOHNSON
JNJ
1/10
Debt: $32.4B 12mo: $2.0B
PFIZER INC
PFE
5/10
Debt: $4.0B 12mo: N/A
AbbVie Inc.
ABBV
5/10
Debt: $64.5B 12mo: $6.0B
Merck & Co., Inc.
MRK
3/10
Debt: N/A 12mo: $2.6B
ELI LILLY & Co
LLY
3/10
Debt: $19.1B 12mo: $781M
BRISTOL MYERS SQUIBB CO
BMY
4/10
Debt: $49.4B 12mo: $2.0B
AMGEN INC
AMGN
5/10
Debt: $60.1B 12mo: $4.6B
GILEAD SCIENCES, INC.
GILD
4/10
Debt: $26.7B 12mo: $2.8B

Data Source: Financial data sourced from SEC EDGAR XBRL filings (10-K annual reports). Most recent filing date: 2026-02-13. Data last fetched: 2026-03-15. Maturity schedules reflect the company's most recently reported debt repayment obligations. Data quality: Limited.